Lineage Cell Therapeutics
  • Company
    • About Us
    • Leadership
    • Board of Directors
    • Careers
    • Contact
  • Pipeline
    • Overview
    • OpRegen® (Dry AMD)
    • OPC1 (Spinal Cord Injury)
    • VAC2 (Immuno-oncology)
  • Technology
    • Lineage Platform
    • Manufacturing
  • Media
  • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Charters and Documents
      • Leadership
      • Board of Directors
      • Committee Composition
    • Analyst Coverage
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Financials & Filings
      • SEC Filings
      • Annual Report and Proxy Information
      • 2018 AgeX Form 10 and Information Statement
      • 2019 Form 8937
    • E-mail Alerts
    • Contact IR
  • Menu Menu
InterviewsPresentationsKOLsPatients
PreviousNext

Interviews, Articles & Podcasts

Please review our forward looking statements on articles, podcasts or recordings

Hopkins Biotech Podcast · Lineage Cell Therapeutics: Building an Allogeneic Cell Transplant Therapy Platform

Hopkins Biotech Podcast
CEO Brian Culley joined the Hopkins Biotech Podcast to discuss Lineage’s proprietary cell therapy platform and next steps for our clinical programs (recorded on September 27th, 2022).

Feb 27, 2023

How Lineage Cell Therapeutics is working to become a leader in cell transplant medicine

On a recent trip to visit with OPC1 recipient Chris Block, CEO Brian Culley sat down to discuss Lineage and the future of cell therapy.

Feb 09, 2023

Genetics, Alzheimer’s And AI — Why 2023 Could Be The Year For Biotech Stocks
CEO Brian Culley joined fellow industry leaders in a roundtable discussion about expectations for biotech market in 2023

Dec 14, 2022

GEN: Genetic Engineering & Biotechnology News

CEO Brian Culley interviewed by Jonathan D Grinstein, PhD

Nov 14, 2022

Evaluate Vantage

Looking for winners in geographic atrophy

Oct 26, 2022

Endpoints News

Lineage Cell Therapeutics opens new California R&D facility and expands Israel manufacturing site

Oct 13, 2022

Health Professional Radio

CEO Brian Culley discusses the latest clinical advancements with the company’s lead cell therapy program as well as its spinal cord injury and non-small cell lung cancer programs

Aug 31, 2022

channelcheck

CEO Brian Culley is joined by Noble Capital Markets Analyst Robert LeBoyer for a Q&A session featuring live audience questions

Aug 30, 2022

Biotech 2050 Podcast · 116. Retinal restoration and visions for growth, Brian Culley, CEO, Lineage Cell Therapeutics

Biotech 2050 Podcast

Episode 116. Retinal restoration and visions for growth, Brian Culley, CEO, Lineage Cell Therapeutics
Aug 24, 2022

The Bio Report · Moving from Preservation to Restoration with Off-the-Shelf Cell Therapies

The Bio Report

Moving from Preservation to Restoration with Off-the-Shelf Cell Therapies
Aug 4, 2022

BioTech IQ Podcast

An inside look at Lineage with Ammon Rivera of BiotechIQ

June 7, 2022

May 27, 2022

LifeSciAdvisors

Lunch with LifeSci Webinar

View the Webinar

May 26, 2022

Dawson James Securities Webinar

Analyst Jason Kolbert interviews Lineage CEO Brian Culley

May 31, 2022

SDBJ

San Diego Business Journal

BIOTECH: INKS $670M DEAL TO BOLSTER PIPELINE
Lineage Unveils Cell Programs

May 9, 2022

This Week in Hearing

Cell Therapy Treatment for Hearing Loss: Interview with Lineage Cell Therapeutics CEO, Brian Culley

Apr 21, 2022

Seeking Alpha

Discussing developing and commercializing cell therapies, competing against Elon Musk’s Neuralink, and the future of cell therapy.

Mar 23, 2022

Presentations from specific events, conferences, or showcases

H.C. Wainwright Global Investment Conference

View Presentation

May 24, 2022

NobleCon18

Lineage Cell Therapeutics – Noble Capital Markets’ Eighteenth Annual Investor Conference

Apr 20, 2022

Advances in the Clinical Development of Oligodendrocyte Progenitor Cells to Treat Spinal Cord Injury

Apr 05, 2021

H.C. Wainwright BIOCONNECT Conference

View Presentation

Jan 10, 2022

Key opinion leaders discuss topics related to Lineage’s clinical programs

Watch the video on CGTLive.com

Richard Fessler, MD, Professor of Neurosurgery, Rush University Medical School, discusses data seen in the phase 1/2 clinical trial of OPC1 for spinal cord injury (watch on CGTLive.com)

Jul 20, 2022

Click to View Presentation

Therapeutic Expert Call to Discuss OpRegen Phase 1/2a Study Interim Results (2020 American Academy of Ophthalmology Update)

Nov 17, 2020

Review of the pathogenesis of AMD and the pathways to CNV and GA

Jordi Monés, M.D., Ph.D., Director, Institut de la Màcula and Director, Principal Investigator and Founder, Barcelona Macula Foundation

New Retina Radio with Christopher D. Riemann, M.D.
Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute

Jun 22, 2020

Click to View Presentation

OpRegen® – A Discussion of Retinal Tissue Regeneration in Dry-AMD with Geographic Atrophy

Jun 08, 2020

Click to Listen

Therapeutic Expert Call to Discuss OpRegen Phase 1/2a Clinical Study Results

Christopher D. Riemann, M.D. Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute

May 11, 2020

OpRegen® Phase 1/2a Clinical Study Results
2020 ARVO Meeting

Christopher D. Riemann, M.D., Cincinnati Eye Institute (CEI)

Why is dry age-related macular degeneration (dry AMD) research so important?

Allen C. Ho, M.D., Wills Eye Hospital Director of Retina Research

Why is spinal cord research so important?

Dr. John Steeves, Emeritus Principal Investigator @ICORD and Professor @UBC

A selection of patient focused media related to our cell therapy programs

The Stem Cellar
The Official Blog of CIRM, California’s Stem Cell Agency

Update on spinal cord injury patient Jake Javier, enrolled in CIRM-funded stem cell clinical trial

OPC1 Program – Patient Spotlight – Jake Javier

In 2016, Jake Javier was paralyzed from the neck down. In late 2022, he is set to graduate from Duke University with his Master’s Degree in Biomedical Engineering, with plans to help those impacted by neurological injuries or diseases.

OPC1 Program – Patient Spotlight – Chris Block

In 2016, Chris severely injured his spine in a biking accident. Learn more about his journey and participation in the OPC1 research study.

Sonia Cohen’s OpRegen Story

OpRegen for Dry AMD | Lineage Cell Therapeutics – Jul 27, 2021

Cheri’s Story

OpRegen for Dry AMD | Lineage Cell Therapeutics – Jun 10, 2021

WDAM7 Mississippi

“New Treatment for Age-Related Dry Macular Degeneration” – May 10, 2021

5 years through the eyes of a mum.

A powerful dramatization of living with the progression of vision loss related to AMD. Source: www.macularsociety.org

Spinal Cord Injury and Lineage’s OPC1 Cell Therapy

An instructive whiteboard video explaining how spinal cord injury disrupts normal bodily function as well as OPC1 administration and mechanism of action.

OPC1 Program – Patient Spotlight – Kris Boesen and Lucas Lindner

Highlighting the progress made by Kris Boesen and Lucas Lindner, both of whom received Lineage’s OPC1 cell therapy following traumatic spinal cord injury (SCI).

Lucas Lindner was paralyzed from the neck down following a car accident. The next year, he threw out the first pitch at a Major League Baseball game.

Watch the video above to learn more about Lucas’ journey.

© Copyright - Lineage Cell Therapeutics, Inc.   |   Terms of Use & Privacy   |   [email protected]
  • Facebook
  • Twitter
  • LinkedIn
Scroll to top